Robert Cameron is a copy editor at Nikkei Asia. He specializes in oncology, focusing on radiation oncology, palliative care, pancreatic cancer research, immunotherapy, and surgery. Robert's work has been featured in Branding in Asia Magazine, Defiance Crescent News, Nature Portfolio, and Cancer Network.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Robert's articles mainly focus on advertising, marketing, branding, and media agencies in the Asia Pacific region. His coverage attributes suggest that he often cites data and incorporates press releases into his articles.
From this information it seems clear that Robert would be interested in pitches related to new data insights or industry reports within the advertising, marketing, and branding sectors in the Asia Pacific region. Providing access to experts who can provide commentary on industry trends supported by relevant data could also be an effective approach for engaging with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Robert Cameron
“Against the backdrop of this uncertain world our report turns to hope as a deliberate choice, to empower us to take control and design our own futures."
USW Local 51M voted to donate Christmas presents totaling more than $1,000 to Christmas for Kids. These gifts were left over from the union’s membership Christmas party. Here, President Bob
By: Robert Cameron, Voichița Gheoca, Ana Maria, Lucian Blaga
Abstract The land snail faunas of limestone gorges of Romanian Carpathians were sampled to test the effect of geographic and environmental factors on the malacofauna richness and composition.
By: Laila A. Gharzai, Faith Abodunrin, Rajat Thawani, Jyoti D. Patel, Edward S. Kim, Joshua K. Sabari, Roy S. Herbst, Robert Cameron, Divya M. Gupta
Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.
By: Joshua K. Sabari, Roy S. Herbst
Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.
By: Joshua K. Sabari, Roy S. Herbst
Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.
Experts on non–small cell lung cancer reflect on clinical trial data to weigh treatment options for patients with EGFR-mutated non–small cell lung cancer.
By: Faith Abodunrin, Roy S. Herbst, Joshua K. Sabari, Jyoti D. Patel, Divya M. Gupta, Rajat Thawani, Robert Cameron, Edward S. Kim, Laila A. Gharzai
Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.
Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
By: Robert Cameron
The Hon. Tony Fitzgerald AC KC developed a set of principles – or charter of governance for those in public office, or candidates for public office, viz,
(833) 317-6278 
